A comprehensive exit readiness checklist built specifically for reproductive endocrinologists and IVF practice owners preparing for acquisition — covering SART outcomes, physician succession, laboratory accreditation, and everything a strategic buyer will scrutinize.
Selling a fertility clinic is one of the most complex transactions in lower middle market healthcare M&A. Buyers ranging from national platforms like US Fertility and CCRM to private equity-backed regional networks will apply rigorous due diligence to your SART/CDC success rates, physician employment agreements, CLIA laboratory accreditation, payer mix, and corporate structure. Most fertility clinic exits require 18 to 24 months of intentional preparation to achieve the 5x–9x EBITDA multiples the market supports. This checklist organizes that preparation into three phases: foundation work you should complete immediately, operational improvements to execute in months six through twelve, and pre-market positioning steps to finalize before engaging a buyer. Each item is rated by impact level and estimated valuation lift so you can prioritize the actions that matter most.
Get Your Free Fertility Clinic Exit ScoreCommission a Quality of Earnings (QoE) Report
Engage a healthcare-focused accounting firm to prepare a third-party QoE report that normalizes founding physician compensation to market rate, strips out personal expenses run through the practice, and identifies any one-time revenue or cost items that distort true EBITDA. Buyers from US Fertility to PE platforms will produce their own QoE — having yours ready prevents surprises and anchors negotiations to your numbers.
Audit SART/CDC ART Outcome Reports for the Last 3 Years
Pull your last three annual SART and CDC ART success rate reports and benchmark your per-transfer live birth rates against national averages by age cohort and cycle type. Buyers treat below-average or unpublished success rates as a significant red flag. If your rates are above average, these reports become a core marketing asset. If they are below average, you have time to investigate causes and address laboratory or clinical protocol issues before going to market.
Verify and Document All Licenses and Accreditations
Confirm that your CLIA certificate, SART membership, CAP laboratory accreditation if applicable, and all state health department facility licenses are current, in good standing, and transferable to a new entity or MSO structure. Identify any that are tied personally to you as the founding physician rather than to the practice entity — these require early resolution to avoid closing delays.
Clarify Your Corporate Entity Structure for CPOM Compliance
Engage a healthcare attorney experienced in your state's corporate practice of medicine (CPOM) doctrine to review your current legal entity structure. If your clinic is organized in a way that a buyer cannot legally acquire operating control — or if a future MSO structure would violate state law — you need to restructure now, not during due diligence. Many PE-backed acquirers require an MSO/PC structure to close.
Compile Three Years of Clean Financial Statements
Prepare accrual-basis financial statements — profit and loss, balance sheet, and cash flow — for the last three full fiscal years plus a current year-to-date. Separate revenue by service line: IVF cycles, frozen embryo transfers, egg freezing, PGT-A, donor egg, and ancillary services. Buyers want to see revenue diversification and will apply different risk assessments to each revenue stream.
Reduce Single-Physician Dependency
The most common value killer in a fertility clinic sale is a practice where all patient relationships, referral networks, and clinical decisions flow through one founding reproductive endocrinologist with no associate RE in place. Begin recruiting, hiring, or formalizing the role of an associate or partner RE under a long-term employment agreement with a non-compete. Buyers will pay significantly more — and accept more favorable deal structures — when the practice is not wholly dependent on one physician.
Secure and Document Physician Employment Agreements and Non-Competes
Ensure all employed reproductive endocrinologists, embryologists, and senior clinical staff have current, enforceable employment agreements with non-solicitation and non-compete provisions. Buyers will scrutinize the duration, geographic scope, and enforceability of these agreements under state law. Agreements that have expired, lack non-competes, or were never executed properly create significant deal risk.
Assess and Document IVF Laboratory Equipment Condition
Commission a maintenance audit of all IVF laboratory equipment including incubators, cryostorage systems, micromanipulation equipment, and air quality systems. Document the age, service history, and estimated remaining useful life of each major asset. Buyers and their technical advisors will inspect the laboratory in detail — undisclosed equipment requiring immediate replacement will surface as a price reduction or capital expenditure escrow holdback at closing.
Diversify and Document Revenue Streams
Formalize and document all ancillary revenue lines beyond IVF cycles: elective egg freezing, PGT-A genetic testing partnerships, donor egg program, male fertility diagnostics, and any employer fertility benefit contracts with platforms like Progyny or WINFertility. Create a revenue bridge showing each service line's contribution, growth trajectory, and margin profile. Buyers pay premium multiples for practices with diversified, recurring revenue that is not solely dependent on fresh IVF cycle volume.
Conduct a HIPAA and Patient Consent Documentation Audit
Engage a healthcare compliance attorney to audit your HIPAA policies, business associate agreements, patient consent forms, embryo storage and disposition agreements, and genetic information handling protocols. Gaps in embryo consent documentation or outdated HIPAA policies are common in independently operated fertility clinics and represent both regulatory and reputational liability that buyers will use to reduce price or require indemnification escrows.
Resolve Outstanding Malpractice Claims and Regulatory Citations
Work with your malpractice carrier and healthcare attorney to close out any open claims, settle pending complaints, and document the resolution of any prior regulatory citations from state health departments, CLIA surveyors, or SART. Buyers will conduct a formal malpractice history review and any open or recently settled claims will require disclosure, representation, and often an indemnification holdback at closing.
Build a Management Layer Independent of the Founding Physician
Develop and document the operational management structure that will continue to run the clinic after you exit or reduce your clinical role. This includes a clinical director or practice administrator with clear responsibilities, a lead embryologist, a patient services coordinator, and documented standard operating procedures. Buyers — especially PE platforms — will not pay full value for a business whose operations collapse when the founder steps away.
Prepare a Confidential Information Memorandum with SART Benchmarking
Work with your M&A advisor to develop a Confidential Information Memorandum (CIM) that leads with your SART outcome data benchmarked against national averages, presents your revenue by service line, highlights your physician team depth, documents your payer mix and any employer benefit contracts, and articulates your market position relative to local competitors. A well-constructed CIM for a fertility clinic accelerates buyer interest from strategic acquirers and PE platforms who evaluate dozens of opportunities annually.
Obtain a Third-Party Practice Valuation
Commission a formal valuation from a healthcare-focused business valuation firm that applies EBITDA multiples specific to the fertility sector, accounts for your SART performance, physician dependency risk, laboratory quality, and payer mix. This valuation serves as your anchor in negotiations with buyers, supports your asking price to LOI, and helps you evaluate whether any given offer is within or below market range for a SART-member fertility clinic of your size.
Negotiate Malpractice Tail Coverage Terms Before Signing
Before engaging buyers, clarify with your malpractice carrier the cost, duration, and responsibility for tail coverage upon your exit from ownership. Tail policies for reproductive endocrinologists can cost $50K–$150K and typically cover a 5-year lookback period. Negotiate in the LOI and purchase agreement who bears this cost — it is a common point of contention that should be resolved in term sheet discussions, not during final documentation.
Run a Controlled Competitive Sale Process
Engage an M&A advisor with specific fertility clinic and healthcare transaction experience to run a structured sale process that generates offers from multiple qualified buyers simultaneously — including PE-backed platforms, regional health systems, and physician group acquirers. A competitive process with multiple LOIs is the single most reliable mechanism for achieving the upper end of the 5x–9x EBITDA multiple range. Sole-source negotiations consistently produce below-market outcomes.
See What Your Fertility Clinic Business Is Worth
Free exit score, valuation range, and personalized action plan — 5 minutes.
Fertility clinics in the lower middle market typically trade at 5x to 9x EBITDA, but the range is not random. Practices with above-average SART success rates, multiple board-certified reproductive endocrinologists under contract, a diversified revenue base including egg freezing and PGT-A, and documented employer fertility benefit contracts consistently achieve the upper half of that range. Single-physician practices with below-average SART outcomes, aging laboratory equipment, or open compliance issues are typically priced toward the lower end — or require significant earnout contingencies. At $1.5M EBITDA, that range translates to $7.5M to $13.5M in enterprise value, making preparation worth hundreds of thousands to millions of dollars in realized proceeds.
No. Fertility clinics are not SBA-eligible due to the healthcare industry exclusion and the typical scale of transactions — most fertility clinic acquisitions exceed SBA loan limits and involve physician licensure requirements that complicate SBA structures. Buyers are typically private equity-backed platforms, health systems, or physician groups using conventional acquisition financing, seller notes, or equity recapitalizations. This means your buyer pool is institutional, not individual searchers using SBA financing, and your deal structure will reflect that — often including earnouts tied to EBITDA growth, physician rollover equity, or seller-financed notes.
The full exit process from initial preparation to closing typically runs 18 to 24 months for a fertility clinic. The preparation phase alone — completing a QoE, auditing SART compliance, securing physician agreements, and addressing any operational gaps — takes 12 to 18 months when done properly. The active marketing and deal process with buyers then adds another 6 to 9 months through LOI, due diligence, and closing. Physicians who try to compress this timeline by going to market unprepared consistently leave money on the table or accept contingent deal structures that delay their actual liquidity. Starting 24 months before your target exit date is the right approach.
A Management Services Organization (MSO) structure separates the business and administrative operations of your clinic from the clinical and medical practice, which must remain under physician ownership in states with corporate practice of medicine (CPOM) laws. In an MSO acquisition, the buyer acquires the MSO entity — which handles billing, staffing, real estate, equipment, and administration — while you or a designated physician retain ownership of the professional corporation (PC) that employs the reproductive endocrinologists and holds the medical licenses. A Professional Services Agreement governs the relationship between the two entities. Most PE-backed fertility platforms and health system acquirers require this structure. Your healthcare attorney should confirm whether your state requires it and whether your current entity structure needs to be reorganized before you go to market.
Employee retention and patient relationship continuity are legitimate concerns and should be addressed directly in your purchase agreement and transition plan. Most institutional buyers of fertility clinics — especially those building national platforms — have strong incentives to retain clinical staff, embryologists, and support teams because patient trust and outcomes are tied directly to those relationships. You should negotiate employee retention commitments, tenure protections for key staff, and a defined clinical transition period during which you remain active as a physician. Your SART-reported success rates are tied to your laboratory team and protocols — buyers know that disrupting these relationships risks the outcome data that justifies their acquisition price.
A Quality of Earnings (QoE) report is an independent financial analysis prepared by an accounting firm that adjusts your reported EBITDA to reflect what a buyer would actually be acquiring. For a fertility clinic, this typically means normalizing your physician compensation from whatever you currently pay yourself to market rate for a board-certified reproductive endocrinologist in your region, removing personal expenses run through the practice, identifying one-time revenues from grant funding or COVID relief programs, and adjusting for any accounting treatments that inflate or distort earnings. If your reported EBITDA is $1.2M but normalized EBITDA after physician compensation adjustment is $1.8M, you have just added $3M to $5M of enterprise value. Conversely, if a buyer's QoE finds adjustments that reduce EBITDA, they will retrade the price. Having your own QoE prepared first allows you to control the narrative and defend your numbers with documented analysis.
SART and CDC ART outcome data is publicly available and every sophisticated buyer will review it before making an offer. Buyers analyze your per-transfer live birth rates by patient age cohort relative to national SART benchmarks and use this data to assess both clinical quality and patient acquisition strength — because patients comparison-shop fertility clinics by published success rates before making cycle decisions. If your rates are above national averages, this is a durable competitive moat and a primary marketing asset in your CIM. If your rates are below average or unpublished, buyers will discount accordingly or require representations about underlying causes. If you have time before going to market, work with your embryology team and reproductive endocrinologist to audit cycle protocols, laboratory air quality, embryo culture conditions, and patient selection criteria — even incremental improvements in reported outcomes over two to three reporting cycles can meaningfully change buyer perception and valuation.
More Fertility Clinic Seller Guides
More Exit Checklists
Get your Fertility Clinic exit score, estimated valuation, and a step-by-step action plan — free, in 5 minutes.
Start Your Free Exit AssessmentFree forever · No broker needed · Takes 5 minutes
For Buyers
For Sellers